Stock market today: Nifty 50, Sensex surge over 1% on gains in RIL, Airtel & pharma stocks

Despite heightening geopolitical tensions, the Indian stock market made a strong recovery in Friday’s session, November 29, with strong support from heavyweights such as Bharti Airtel, Reliance Industries, and ICICI Bank helping the frontline indices finish the last trading day of November in positive territory.

The Nifty 50 ended the session with a gain of 0.91%, closing at 24,131, while the Sensex rallied by 0.91%, finishing at 79,760. However, the broader markets underperformed the benchmark indices. The Nifty Midcap 100 rose by 0.15%, closing at 56,384, while the Nifty SmallCap 100 ended the session with a 0.75% gain, at 18,649, compared to the previous closing.

Although heavyweights supported the benchmark indices in the final trading session, they weren’t enough to push November’s performance into the green. Both the Nifty 50 and Sensex ended the month with a drop of up to 0.5%, though the pace of selling slowed compared to October, when both indices fell over 6%, marking their steepest monthly drop since March 2020.

Additionally, November was the most volatile month for both the indices since June. The Nifty 50 swung by 1,274 points, while the Sensex fluctuated by 3,767 points.

Sectoral Performance: Pharma shines, realty lags

Among sectoral indices, Nifty Pharma emerged as the top performer with a gain of 2.35%, breaking its 3-day losing streak. Nineteen of the 20 constituents of the index ended the session higher, with Torrent Pharma leading the way, rallying by 4%. Divi’s Laboratories, Alkem Laboratories, Natco Pharma, and three other stocks also closed with gains between 3% and 4%.

Cipla shares jumped nearly 3% after domestic brokerage firm Prabhudas Lilladher upgraded the stock to a ‘buy’ rating and raised its target price by 7% to 1,730. The brokerage highlighted Cipla’s strong U.S. portfolio, including respiratory drugs, injectables, and peptides, as well as new product launches expected to drive $1 billion in sales by FY27. 

The timely launch of cancer drug Abraxane and asthma drug Advair could yield annual sales of $100-120 million amid limited competition, it said. Other sectoral indices, including Nifty Media, Nifty Energy, Nifty Oil & Gas, and Nifty Consumer Durables, ended the session with gains exceeding 1%.

On the losing side, Nifty Realty and Nifty PSU Bank closed with losses of 0.59% and 0.56%, respectively.

Spread the love

Aniket Pujari

Aniket Pujari is a visionary entrepreneur and dedicated content creator who has made significant contributions to the digital media landscape. As the founder of Minute To Know News, he has established himself as a leading figure in the world of finance, cryptocurrencies, and Internet-related topics.

Related Posts

Salesforce shares surge 11% to hit record high after AI boom fuels Q3 earnings; stock up 26% YTD

Salesforce Inc. shares hit a record high on Wednesday after the company reported better-than-expected quarterly revenue, boosting hopes for the company’s much-hyped artificial intelligence strategy. Sales increased 8.3% to $9.44…

Spread the love

Trump’s defense secretary pick Pete Hegseth’s faces scrutiny amid allegations; DeSantis discussed as replacement

Pete Hegseth, Donald Trump’s nominee for secretary of defense, is fighting to retain his Cabinet position as questions about his personal conduct intensify. Amid growing concerns about his path to…

Spread the love

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Nuvei launches blockchain payment solution for LATAM

Nuvei launches blockchain payment solution for LATAM

Solana Whales Begin Accumulation Spree Amid Predictions of SOL at $600

Solana Whales Begin Accumulation Spree Amid Predictions of SOL at $600

Salesforce shares surge 11% to hit record high after AI boom fuels Q3 earnings; stock up 26% YTD

ApeCoin price could hit $5 as APE forms 2 rare patterns

ApeCoin price could hit $5 as APE forms 2 rare patterns

Trump’s defense secretary pick Pete Hegseth’s faces scrutiny amid allegations; DeSantis discussed as replacement

Trump’s defense secretary pick Pete Hegseth’s faces scrutiny amid allegations; DeSantis discussed as replacement

Trump picks Peter Navarro as top trade advisor

Trump picks Peter Navarro as top trade advisor